First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study

Abstract Background and Aims Sequential therapy with molecular‐targeted agents (MTAs) is considered effective for unresectable hepatocellular carcinoma (HCC) patients. This study purposed to evaluate the efficacy of sequential therapy with sorafenib (SORA) as a first‐line therapy and to investigate...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Shigeo Shimose, Atsushi Hiraoka, Masahito Nakano, Hideki Iwamoto, Masatoshi Tanaka, Takaaki Tanaka, Kazunori Noguchi, Hajime Aino, Kei Ogata, Masahiko Kajiwara, Satoshi Itano, Yoshinori Yokokura, Taizo Yamaguchi, Hiroshi Kawano, Norito Matsukuma, Hideya Suga, Takashi Niizeki, Tomotake Shirono, Yu Noda, Naoki Kamachi, Shusuke Okamura, Takumi Kawaguchi, Hironori Koga, Takuji Torimura
Format:	article
Langue:	EN
Publié:	Wiley 2021
Sujets:	carcinoma hepatocellular nonalcoholic steatohepatitis sequential therapy sorafenib Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Accès en ligne:	https://doaj.org/article/0894e9642c0c4631b38c4aa5d3985b9c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Soyez le premier à ajouter un commentaire!

First‐line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study

Documents similaires